title: New insights into the treatment of severe asthma in children.
abstract: Severe asthma accounts for 0.5% of the general paediatric population and 4.5% of children with asthma, representing the major burden of asthma-health-care-associated costs. After ensuring a diagnosis of asthma and excluding difficult-to-treat patients with co-morbidities and non-adherence profiles, there remains children with real therapy-resistant asthma for whom the recommendations are to treat beyond guidelines. We describe new insights into the treatment of severe asthma in children, regarding both "classic drugs" (corticosteroids, bronchodilators) and innovative biological therapies targeting airway inflammation and impaired innate immunity. All of these new avenues remain to be studied and validated in children and will require fine clinical and biological phenotyping.
authors.affiliation: Paediatric Pulmonology and Allergology Department, Hôpitaux pédiatriques de Nice CHU-Lenval, Nice, F-06200, France; Université de Nice Sophia Antipolis, Nice, F-06000, France. Electronic address: giovannini-chami.l@pediatrie-chulenval-nice.fr.
authors.forename: Lisa
authors.initials: L
authors.lastname: Giovannini-Chami
authors.affiliation: Paediatric Pulmonology and Allergology Department, Hôpitaux pédiatriques de Nice CHU-Lenval, Nice, F-06200, France; Université de Nice Sophia Antipolis, Nice, F-06000, France.
authors.forename: Marc
authors.initials: M
authors.lastname: Albertini
authors.affiliation: Paediatric Pulmonology and Allergology Department, AP-HP, Hôpital Necker Enfants Malades, Paris, F-75015, France; Université Paris Descartes-Paris 5, Paris, F-75005, France.
authors.forename: Pierre
authors.initials: P
authors.lastname: Scheinmann
authors.affiliation: Paediatric Pulmonology and Allergology Department, AP-HP, Hôpital Necker Enfants Malades, Paris, F-75015, France; Université Paris Descartes-Paris 5, Paris, F-75005, France.
authors.forename: Jacques
authors.initials: J
authors.lastname: de Blic
mesh_terms: D000293:Adolescent; D000328:Adult; D018927:Anti-Asthmatic Agents / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy*; D001691:Biological Therapy / Q000379:methods*; D001993:Bronchodilator Agents / Q000627:therapeutic use*; D002648:Child; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans
chemical_list: D018927:Anti-Asthmatic Agents; D001993:Bronchodilator Agents; D005938:Glucocorticoids
keywords: Anti-cytokine; Antiviral drugs; Bronchodilators; Inhaled corticosteroids; Innovative therapies; Omalizumab